September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Caspase-9 inhibition by Pen1-XBir3 abrogates retinal edema
Author Affiliations & Notes
  • Maria Avrutsky
    Pathology and Cell Biology, Columbia University, New York, New York, United States
  • Ying Jean
    Pathology and Cell Biology, Columbia University, New York, New York, United States
  • Guy Salvesen
    Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States
  • Carol M Troy
    Pathology and Cell Biology, Columbia University, New York, New York, United States
    Neurology, Columbia University, New York, California, United States
  • Footnotes
    Commercial Relationships   Maria Avrutsky, None; Ying Jean, None; Guy Salvesen, None; Carol Troy, None
  • Footnotes
    Support  R01NS081333, T32 EY013933
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5351. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria Avrutsky, Ying Jean, Guy Salvesen, Carol M Troy; Caspase-9 inhibition by Pen1-XBir3 abrogates retinal edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5351. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Macular edema results from fluid accumulation in the macula due to leaky blood vessels, and is a common complication of diabetes and retinal vein occlusion (RVO). Despite available therapies, an estimated 50% of patients do not respond to treatment. We identified caspase-9, a protease traditionally associated with apoptosis, as an essential component in edema formation. To test the therapeutic potential of modulating caspase-9 activity in edema, we developed a highly-specific caspase-9 inhibitor by utilizing the XBir3 domain of XIAP.

Methods : We induced retinal edema in 2-4 month-old C57Bl/6J mice, and endothelial cell specific caspase-9 knockout (caspase-9Flox/Tek-Cre) mice. We employed two models of retinal edema: intravitreal injection of hypertonic saline (5μl, 10X PBS), and RVO. RVO was achieved by tail-vein injection of rose bengal (150μl, 5mg/mL), followed by laser photocoagulation of retinal veins using 50mW output and 2.5 sec laser duration. In vivo analyses – optical coherence tomography (OCT) and fluorescein angiography - were conducted with the Micron IV system (Phoenix Research Labs). We generated Pen1-XBir3 by crosslinking XBir3 to a cell permeant peptide, Pen1 (1:2 molar ratio, incubated at 37°C for 2 hrs). Mice received eyedrops containing 10μg Pen1-XBir3 immediately following retinal injury.

Results : Both injury models induce acute retinal edema as measured by OCT (injection model N=3, P<0.01; RVO model N=5, P<.001), fluorescein angiography, fluorescein-dextran leakage in retinal flatmounts (N=4, P<.05), and H&E staining of retinal cross-sections (injection model N=3, P<0.001). Concomitantly, caspase-9 and VEGF levels increase after injury, as measured by western blot and immunohistochemistry. Caspase-9 Flox/Tek-Cre mice develop substantially less edema compared to wildtype animals (injection model N=3, P<.05), confirming the importance of endothelial expression of caspase-9 in edema formation. Our findings reveal that Pen1-XBir3 inhibits caspase-9 activity, and can be delivered to the retina via eyedrop. Pen1-XBir3 reduces the severity of retinal edema (injection model N=3, P<0.01; RVO model N=10, P<.001) and prevents the induction of VEGF (N=4, P<0.05) in both models.

Conclusions : Our studies indicate that endothelial caspase-9 plays an essential role in regulating edema pathogenesis. Moreover, Pen1-XBir3 abrogates the edema and may be a potential novel therapy for individuals suffering from macular edema.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.



This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.